Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International Journal of Clinical Practice Année : 2009

Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases

Richard Kay
  • Fonction : Auteur
  • PersonId : 880867
Cyrus Cooper
  • Fonction : Auteur
  • PersonId : 880868
Patrick Haentjens
  • Fonction : Auteur
  • PersonId : 880869
Dirk Vanderschueren
  • Fonction : Auteur
  • PersonId : 880870
Filip Callewaert
  • Fonction : Auteur
  • PersonId : 880871
Koen Milisen
  • Fonction : Auteur
  • PersonId : 880872
Serge Ferrari
  • Fonction : Auteur
  • PersonId : 880873

Résumé

Aims: The efficacy of treatments for osteoporosis can be evaluated using a variety of study designs. This article aims to comprehensively review the evidence for bisphosphonate anti-fracture efficacy in postmenopausal women, discussing the strengths and limitations associated with each study method. Methods: Literature analysis included English-language publications reporting results of randomised controlled trials (RCTs), post hoc analyses, meta-analyses and observational studies evaluating the efficacy of alendronate (ALN), ibandronate (IBN), risedronate (RIS) and zoledronate (ZOL), with an initial sample size ≥ 100 patients, and follow-up data for at least 1 year. Results: Primary and secondary analyses of RCT data suggest differences among bisphosphonates with regard to site-specific anti-fracture efficacy and onset of fracture risk reduction. While some observational studies indicate differences in clinical outcomes among these agents, others report similar effectiveness. ALN and RIS data demonstrate sustained fracture protection for up to 10 and 7 years of treatment, respectively. The efficacy of IBN and ZOL has been evaluated for up to 3 and 5 years, respectively. Conclusions: Understanding of the benefits of bisphosphonate treatment can be maximised by evaluating complementary data from RCTs and observational database studies. Fracture risk reduction with bisphosphonates is shown in RCTs and in real-world clinical settings.

Mots clés

Fichier principal
Vignette du fichier
PEER_stage2_10.1111%2Fj.1742-1241.2009.02206.x.pdf (784.22 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-00527660 , version 1 (20-10-2010)

Identifiants

Citer

Steven Boonen, Richard Kay, Cyrus Cooper, Patrick Haentjens, Dirk Vanderschueren, et al.. Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases. International Journal of Clinical Practice, 2009, 63 (12), pp.1792. ⟨10.1111/j.1742-1241.2009.02206.x⟩. ⟨hal-00527660⟩

Collections

PEER
42 Consultations
155 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More